Drug Database
Back to search

Japan· JP-1139002F1070

カルバマゼピン

A carbamazepine product containing カルバマゼピン, registered in Japan by 共和薬品工業, on the national reimbursement list. The same ATC class is registered in 18 of our 19 countries.

On Japan’s NHI price listATC N03AF01

Checked against MHLW / PMDA (Japan) on

Informational only — not a medical device.

SOURCE REGISTER · JPMHLW / PMDA (Japan)normalisedカルバマゼピンATCN03AF01REGISTER NO.JP-1139002F1070PACKS LISTED0CHECKEDSeptember 25, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about カルバマゼピンAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Carbamazepine is registered in 18 of 19 countries.

Countries holding a registration under ATC N03AF01 (carbamazepine), each read from that country’s own register.

  • This record: Japan, from MHLW / PMDA (Japan)
  • 10 of them publish a price we can compare per daily dose
Search carbamazepine products by name

Carbamazepine · ATC N03AF01

18 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of carbamazepine costs, country by country.

Normalised to the WHO defined daily dose (1 g), the median price runs from $0.39 in France to $1.99 in United States — a ×5.2 gap.

  • 4 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
  • US figures are pharmacy acquisition cost (CMS NADAC), not retail
Open the full comparison — free accountDrug prices for market access

Carbamazepine · price per daily dose (1 g)

USD · FX 28 Sept 2026

  • US United States$1.99 (acquisition cost)
  • CH Switzerland$1.35
  • IT Italy$0.46
  • FR France$0.39
Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

MHLW / PMDA (Japan)
Active substance
カルバマゼピン
Manufacturer
共和薬品工業
Country
Japan (JP)
ATC code
N03AF01
ATC class
Carbamazepine
Defined daily dose
1 g, O
Reimbursed
Yes
Source register
MHLW / PMDA (Japan)
Last checked
September 25, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

614 interactions on record for carbamazepine.

Graded by severity as the source publishes them — 136 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check carbamazepine against other medicinesHow interaction checks work

Carbamazepine · interactions on record

614 records

  • 136 severe
  • 250 moderate
  • 6 minor
  • 133 info

Most severe, free to view

  • RolapitantA04AD14severe
  • NaloxegolA06AH03severe
  • NaldemedineA06AH05severe
  • EliglustatA16AX10severe

89 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same class

Other records under N03AF01

Carbamazepine, as other registers publish it.

All carbamazepine products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d0eb1fcb-146f-454a-9114-789e9f2a4bf1
GET /v1/drugs/d0eb1fcb-146f-454a-9114-789e9f2a4bf1?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "spec": "２００ｍｇ１錠",
  "marks": null,
  "source": "mhlw",
  "remarks": null,
  "yj_code": "1139002F1070",
  "category": "内用薬",
  "price_yen": 10,
  "generic_name": "カルバマゼピン",
  "product_name_jp": null,
  "therapeutic_class": "1139",
  "transitional_expiry": null
}
API referenceMCP serverPlans

See everything about carbamazepine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console